KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Equity Average (2016 - 2025)

Travere Therapeutics' Equity Average history spans 15 years, with the latest figure at $94.2 million for Q4 2025.

  • For Q4 2025, Equity Average rose 558.18% year-over-year to $94.2 million; the TTM value through Dec 2025 reached $94.2 million, up 558.18%, while the annual FY2025 figure was $87.0 million, 33.08% down from the prior year.
  • Equity Average reached $94.2 million in Q4 2025 per TVTX's latest filing, up from $53.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $347.5 million in Q2 2021 to a low of -$7.7 million in Q3 2024.
  • Average Equity Average over 5 years is $151.0 million, with a median of $133.1 million recorded in 2022.
  • Peak YoY movement for Equity Average: plummeted 103.86% in 2024, then soared 794.53% in 2025.
  • A 5-year view of Equity Average shows it stood at $304.7 million in 2021, then tumbled by 76.45% to $71.8 million in 2022, then skyrocketed by 234.83% to $240.3 million in 2023, then crashed by 94.04% to $14.3 million in 2024, then soared by 558.18% to $94.2 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Equity Average are $94.2 million (Q4 2025), $53.2 million (Q3 2025), and $32.8 million (Q2 2025).